CTEC.L Stock Analysis
CT
Neutral
Based on Eyestock quantitative analysis, CTEC.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Market cap $B
6.012
Dividend yield
2.08 %
Shares outstanding
2 043.87 B
ConvaTec Group Plc operates as holding company, which engages in medical business. The company is headquartered in Reading, Berkshire. The company went IPO on 2016-10-26. The firm is focused on solutions for the management of chronic conditions, with market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. The company markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care includes advanced solutions for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories and personalized services for individuals with a stoma. Its Continence and Critical Care includes products and services for people with urinary continence issues, and other devices for critical care. Its Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.